Eye drop treatment for dry AMD shows promise in Phase 2 trial

view article

Published at: www.othera.com

Advantage of topical treatment vs intra-vitreal injections

April 16, 2009

Analysis by: GLG Expert Contributor

Currently the only treatmen  for wet AMD is intravitreal razimomab. This requires monthly injections in a facility.  There is also the possibilty of hemorrhage or infection.

Othera's Eye Drop to Cure ARMD Seems Promising But Too Early to Tell

April 16, 2009

Analysis by: GLG Expert Contributor

An eye drop that stabilizes the most common form of AMD is encouraging.  The ability for an eye drop to be effective is curious.  Historically it has been difficult to get any medication effectively delivered to the retina via topical medications.  The development of geographic atrophy is very, very slow and it is surprising that a positive trend can be noted in such a short time.

Rahul KhuranaClinical Assistant Professor of Ophthalmology THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - CC

Promising Eye Drop for Dry Age-Related Macular Degeneration.

April 15, 2009

Othera Pharmaceuticals, Inc. announced positive interim data results from its Phase 2 trial of OT-551 in treating geographic atrophy (GA) in dry AMD. OT-551 is a topically-dosed, patented small molecule that acts on oxidative stress and disease-induced inflammation. The 12-month findings from the two-year trial suggest an emerging trend for reducing moderate vision loss in 137 patients with GA who were treated with OT-551 compared with placebo.